Email updates

Keep up to date with the latest news and content from Journal of Experimental & Clinical Cancer Research and BioMed Central.

Open Access Highly Accessed Research

Expression of RABEX-5 and its clinical significance in prostate cancer

Hongtuan Zhang1, Shang Cheng1, Andi Wang1, Hui Ma2, Bing Yao1, Can Qi1, Ranlu Liu1, Shiyong Qi1 and Yong Xu1*

Author Affiliations

1 Department of Urology, National Key Clinical Specialty of Urology, Second Hospital of Tianjin Medical University, Tianjin Key Institute of Urology, Tianjin medical university, Tianjin, China

2 Department of gynaecology and obstetrics, Second Hospital of Tianjin Medical University, Tianjin medical university, Tianjin, China

For all author emails, please log on.

Journal of Experimental & Clinical Cancer Research 2014, 33:31  doi:10.1186/1756-9966-33-31

Published: 9 April 2014



While recent research has shown that expression of RABEX-5 in breast cancer and colorectal cancer has a crucial impact on tumor development, there is little information regarding RABEX-5 expression in prostate cancer. This study investigated the expression of RABEX-5 in prostate cancer by real time quantitative polymerase chain reaction and evaluated its association with clinicopathological variables, including prostate cancer patient prognosis.


A total of 180 patients with primary prostate cancer treated by radical prostatectomy were enrolled. Real time quantitative polymerase chain reaction was utilized to investigate mRNA expression level of RABEX-5 in 180 paired prostate cancer/adjacent non-cancerous tissues. RABEX-5 mRNA expression was divided into high expression group and low expression group and correlations between RABEX-5 mRNA and clinicopathological factors were then evaluated. Kaplan-Meier plots and Cox proportional hazards regression model were used to analyze the association between RABEX-5 mRNA expression and prognosis of patients with prostate cancer.


Our study showed that RABEX-5 mRNA was significantly upregulated in prostate cancer tissues. The data indicated that high expression of RABEX-5 mRNA was significantly associated with lymph node metastasis (P = 0.001), clinical stage (P = 0.004), biochemical recurrence (P = 0.009), preoperative prostate-specific antigen (P < 0.001), and Gleason score (P < 0.001). High RABEX-5 mRNA expression was a significant predictor of poor biochemical recurrence free survival and overall survival both in univariate and multivariate analysis.


This is to our knowledge the first report investigating tumor RABEX-5 mRNA expression level in prostate cancer. We have shown that high RABEX-5 mRNA expression is a strong predictor of poor prognosis in prostate cancer patients treated by radical prostatectomy, and multivariate analysis confirmed RABEX-5 mRNA as an independent prognostic factor.